Curiteva announced that over 1,000 patients have been treated with the novel 3D-printed Inspire Cervical Trabecular PEEK Interbody Fusion System, resulting in over 2,000 Inspire implants placed in patients. The Inspire Cervical System was introduced with limited launch in 2023, followed by full commercialization in July.
The Inspire platform is manufactured with a proprietary, patented Fused Filament Fabrication 3D printer designed, programmed and built by Curiteva. This additive process produces a fully interconnected and integrated porous structure traversing the entire implant to promote osseointegration, improve radiographic assessment and deliver superior biomechanics. The first-to-market combination of the HAFUSE nanotechnology surface treatment and novel porous PEEK structure creates a hydrophilic, bioactive environment for cell attachment, proliferation and healing in pre-clinical animal and in vitro studies.
Chad Falciani, Founder and Chairman of the board for Curiteva, commented, “Next month we will be expanding our Inspire Technology into lumbar, adding momentum to our growth in the quarters to come.”
Curiteva announced that over 1,000 patients have been treated with the novel 3D-printed Inspire Cervical Trabecular PEEK Interbody Fusion System, resulting in over 2,000 Inspire implants placed in patients. The Inspire Cervical System was introduced with limited launch in 2023, followed by full commercialization in July.
The Inspire...
Curiteva announced that over 1,000 patients have been treated with the novel 3D-printed Inspire Cervical Trabecular PEEK Interbody Fusion System, resulting in over 2,000 Inspire implants placed in patients. The Inspire Cervical System was introduced with limited launch in 2023, followed by full commercialization in July.
The Inspire platform is manufactured with a proprietary, patented Fused Filament Fabrication 3D printer designed, programmed and built by Curiteva. This additive process produces a fully interconnected and integrated porous structure traversing the entire implant to promote osseointegration, improve radiographic assessment and deliver superior biomechanics. The first-to-market combination of the HAFUSE nanotechnology surface treatment and novel porous PEEK structure creates a hydrophilic, bioactive environment for cell attachment, proliferation and healing in pre-clinical animal and in vitro studies.
Chad Falciani, Founder and Chairman of the board for Curiteva, commented, “Next month we will be expanding our Inspire Technology into lumbar, adding momentum to our growth in the quarters to come.”
Copy to clipboard 
